HN2000000137A - Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas - Google Patents

Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas

Info

Publication number
HN2000000137A
HN2000000137A HN2000000137A HN2000000137A HN2000000137A HN 2000000137 A HN2000000137 A HN 2000000137A HN 2000000137 A HN2000000137 A HN 2000000137A HN 2000000137 A HN2000000137 A HN 2000000137A HN 2000000137 A HN2000000137 A HN 2000000137A
Authority
HN
Honduras
Prior art keywords
pyrimidine
metaloproteinase
triones
inhibiting
trionas
Prior art date
Application number
HN2000000137A
Other languages
English (en)
Inventor
Julian Blagg
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HN2000000137A publication Critical patent/HN2000000137A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

LA PRESENTE INVENCION SE REFIERE PIRIMIDINA-2,4,6-TRIONAS INHIBIDORES DE METALOPROTEINASAS, Y A COMPOSICIONES FARMACEUTICAS Y PROCEDIMIENTOS DE TRATAMIENTO DE LA INFLAMACION, EL CANCER, ASI COMO DE OTROS TRASTORNOS.
HN2000000137A 1999-08-12 2000-07-20 Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas HN2000000137A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14854799P 1999-08-12 1999-08-12

Publications (1)

Publication Number Publication Date
HN2000000137A true HN2000000137A (es) 2001-02-02

Family

ID=22526231

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2000000137A HN2000000137A (es) 1999-08-12 2000-07-20 Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas

Country Status (41)

Country Link
US (1) US6579982B1 (es)
EP (1) EP1202974B1 (es)
JP (1) JP2003507371A (es)
KR (2) KR20040073608A (es)
CN (1) CN1156454C (es)
AR (1) AR025091A1 (es)
AT (1) ATE309224T1 (es)
AU (1) AU773751B2 (es)
BG (1) BG106406A (es)
BR (1) BR0013081A (es)
CA (1) CA2381551A1 (es)
CO (1) CO5180629A1 (es)
CR (1) CR6565A (es)
CZ (1) CZ2002355A3 (es)
DE (1) DE60023903D1 (es)
EA (1) EA004680B1 (es)
EC (1) ECSP003610A (es)
EE (1) EE200200069A (es)
GE (1) GEP20053424B (es)
GT (1) GT200000137A (es)
HK (1) HK1045995B (es)
HN (1) HN2000000137A (es)
HR (1) HRP20020129A2 (es)
HU (1) HUP0202501A3 (es)
IL (1) IL148035A0 (es)
IS (1) IS6248A (es)
MA (1) MA26812A1 (es)
MX (1) MXPA02001561A (es)
NO (1) NO20020662L (es)
NZ (1) NZ516562A (es)
OA (1) OA12000A (es)
PA (1) PA8498701A1 (es)
PE (1) PE20010491A1 (es)
PL (1) PL353871A1 (es)
SK (1) SK1652002A3 (es)
TN (1) TNSN00169A1 (es)
TR (1) TR200200381T2 (es)
UY (1) UY26285A1 (es)
WO (1) WO2001012611A1 (es)
YU (1) YU6602A (es)
ZA (1) ZA200201070B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
EA200300409A1 (ru) * 2000-10-26 2003-08-28 Пфайзер Продактс Инк. Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназы
CN1501937A (zh) * 2000-10-26 2004-06-02 �Ʒ� 螺-嘧啶-2,4,6-三酮金属蛋白酶抑制剂
MXPA03005870A (es) 2001-02-14 2005-02-14 Warner Lambert Co Inhibirores de benzotiadiazina de metaloproteinasas de la matriz.
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DE60236851D1 (en) 2001-02-14 2010-08-12 Warner Lambert Co Pyrimidinmatrixmetalloproteinaseinhibitoren
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2003081838A (ja) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6936620B2 (en) 2001-12-20 2005-08-30 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003220401A1 (en) 2002-03-18 2003-10-08 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
JP2005529889A (ja) * 2002-04-26 2005-10-06 ファイザー・プロダクツ・インク ピリミジン−２，４，６−トリオンメタロ−プロテイナーゼ阻害剤
DE60302150D1 (en) * 2002-04-26 2005-12-08 Pfizer Prod Inc N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren
JP2005527598A (ja) * 2002-04-26 2005-09-15 ファイザー・プロダクツ・インク トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
MXPA05001785A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de cromona como inhibidores de las metaloproteinasas de matriz.
AU2003253176A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
BR0313724A (pt) 2002-08-13 2005-06-28 Warner Lambert Co Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
WO2004014908A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
CA2497656A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
ES2537514T3 (es) 2003-04-04 2015-06-09 Incyte Corporation Composiciones, métodos y kits relacionados con la escisión de HER-2
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US20150366275A1 (en) * 2014-06-19 2015-12-24 Gyula Cserfoi Wearable Signaling Device
GB201705255D0 (en) 2017-03-31 2017-05-17 Univ I Tromsø - Norges Arktiske Univ Bioactive cyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263932A1 (en) * 1996-08-28 1998-03-05 Yetunde Olabisi Taiwo 1,4-heterocyclic metalloprotease inhibitors
DE69831233T2 (de) * 1997-06-21 2006-06-01 Roche Diagnostics Gmbh Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung

Also Published As

Publication number Publication date
CN1156454C (zh) 2004-07-07
EA200200058A1 (ru) 2002-06-27
IS6248A (is) 2002-01-25
CO5180629A1 (es) 2002-07-30
NO20020662L (no) 2002-04-09
ECSP003610A (es) 2002-03-25
UY26285A1 (es) 2001-03-16
PL353871A1 (en) 2003-12-01
WO2001012611A1 (en) 2001-02-22
EP1202974A1 (en) 2002-05-08
YU6602A (sh) 2004-11-25
US6579982B1 (en) 2003-06-17
CZ2002355A3 (cs) 2002-07-17
HUP0202501A3 (en) 2003-02-28
IL148035A0 (en) 2002-09-12
AU773751B2 (en) 2004-06-03
CA2381551A1 (en) 2001-02-22
KR20040073608A (ko) 2004-08-19
HUP0202501A2 (hu) 2002-12-28
TR200200381T2 (tr) 2002-05-21
OA12000A (en) 2006-04-18
EA004680B1 (ru) 2004-06-24
DE60023903D1 (de) 2005-12-15
ATE309224T1 (de) 2005-11-15
AU6010500A (en) 2001-03-13
MA26812A1 (fr) 2004-12-20
BR0013081A (pt) 2002-04-23
PE20010491A1 (es) 2001-04-25
NZ516562A (en) 2003-06-30
GEP20053424B (en) 2005-01-25
TNSN00169A1 (fr) 2005-11-10
SK1652002A3 (en) 2002-09-10
HK1045995A1 (en) 2002-12-20
KR20020047119A (ko) 2002-06-21
BG106406A (en) 2002-09-30
JP2003507371A (ja) 2003-02-25
MXPA02001561A (es) 2002-07-02
EP1202974B1 (en) 2005-11-09
NO20020662D0 (no) 2002-02-11
CR6565A (es) 2004-02-23
EE200200069A (et) 2003-04-15
ZA200201070B (en) 2003-04-30
HRP20020129A2 (en) 2004-04-30
GT200000137A (es) 2002-02-01
CN1368963A (zh) 2002-09-11
PA8498701A1 (es) 2002-08-26
AR025091A1 (es) 2002-11-06
HK1045995B (zh) 2004-12-31

Similar Documents

Publication Publication Date Title
HN2000000137A (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
ECSP034568A (es) Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona
DOP2003000632A (es) Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona
AU3652102A (en) Compounds and their uses
TW200512205A (en) Quinazoline derivatives
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
MY139355A (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
HK1102991A1 (en) Pharmaceutical formulation of decitabine
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
MXPA05009535A (es) Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos.
HN2000000268A (es) Compuestos , composiciones y metodos para estimular el crecimiento y elongacion de neuronas
HN2001000277A (es) PIRROLO [2,1 - a] DIHIDROISOQUINOLINAS
BR0313385A (pt) Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
MY148647A (en) Pharmaceutical compositions comprising a camtothecin derivative
NI200300045A (es) Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina
AU4910500A (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
WO2002076397A3 (en) Telomerase inhibitors and methods of their use
BRPI0414778A (pt) 6-aril-7-halo-imidazo[1,2-a]pirimidinas como agentes anticáncer
BRPI0419229A (pt) derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
BRPI0414423A (pt) inibidores de pace4, suas composições farmacêuticas e respectivos usos